/MNPR

MNPR Stock - Monopar Therapeutics Inc.

Q: What is the analyst price target for MNPR?

Analyst price target information is not currently available for MNPR.

Q: What is MNPR's market cap?

Market capitalization information is not currently available for MNPR.

Healthcare|Biotechnology|NASDAQ

$67.04+3.09%

+$2.01 (+3.09%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+77.5%upside

Target: $119.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MNPR

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.47

52W High$105.00

52W Low$24.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-16,161,721	$-8,831,235	$-10,536,877	$-9,127,248	$-6,508,875
Net Income	$-15,586,419	$-8,402,196	$-10,515,638	$-9,103,224	$-6,304,573
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.36	$-0.58	$-0.83	$-0.73	$-0.58

Company Overview

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Visit Website

Earnings History & Surprises

MNPR

Beat Rate

68%

Last 19 quarters

Avg Surprise

-13.8%

EPS vs Estimate

Beats / Misses

13/6

Last 12 quarters

Latest EPS

$-0.48

Q4 2025

EPS Surprise History

Q1 24

+29.4%

$-0.60vs$-0.85

Q2 24

+41.2%

$-0.50vs$-0.85

Q3 24

-11.1%

$-0.50vs$-0.45

Q4 24

+19.6%

$-0.37vs$-0.46

Q1 25

-519.4%

$-2.23vs$-0.36

Q2 25

+41.5%

$-0.38vs$-0.65

Q3 25

+25.5%

$-0.35vs$-0.47

Q4 25

-4.3%

$-0.48vs$-0.46

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 30, 2026	$-0.55	—	—	—
Q4 2025	Nov 13, 2025	$-0.46	$-0.48	-4.3%	✗ MISS
Q3 2025	Aug 12, 2025	$-0.47	$-0.35	+25.5%	✓ BEAT
Q2 2025	May 13, 2025	$-0.65	$-0.38	+41.5%	✓ BEAT
Q1 2025	Mar 31, 2025	$-0.36	$-2.23	-519.4%	✗ MISS
Q4 2024	Nov 8, 2024	$-0.46	$-0.37	+19.6%	✓ BEAT
Q3 2024	Aug 9, 2024	$-0.45	$-0.50	-11.1%	✗ MISS
Q2 2024	May 9, 2024	$-0.85	$-0.50	+41.2%	✓ BEAT
Q1 2024	Mar 28, 2024	$-0.85	$-0.60	+29.4%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.95	$-0.70	+26.3%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.95	$-0.80	+15.8%	✓ BEAT
Q2 2023	May 11, 2023	$-1.00	$-0.95	+5.0%	✓ BEAT
Q1 2023	Mar 23, 2023	$-1.05	$-1.10	-4.8%	✗ MISS
Q4 2022	Nov 10, 2022	$-1.15	$-0.95	+17.4%	✓ BEAT
Q3 2022	Aug 11, 2022	$-1.05	$-1.10	-4.8%	✗ MISS
Q2 2022	May 12, 2022	$-1.20	$-0.95	+20.8%	✓ BEAT
Q1 2022	Mar 24, 2022	$-0.90	$-1.05	-16.7%	✗ MISS
Q4 2021	Nov 12, 2021	$-1.10	$-1.00	+9.1%	✓ BEAT
Q3 2021	Aug 12, 2021	$-1.05	$-0.85	+19.0%	✓ BEAT
Q2 2021	May 13, 2021	$-1.10	$-0.80	+27.3%	✓ BEAT

Frequently Asked Questions about MNPR

What is MNPR's current stock price?

Monopar Therapeutics Inc. (MNPR) is currently trading at $67.04 per share. The stock has moved +3.09% today.

What is the analyst price target for MNPR?

The average analyst price target for MNPR is $119.00, based on 1 analyst.

What sector is Monopar Therapeutics Inc. in?

Monopar Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is MNPR's market cap?

Monopar Therapeutics Inc. has a market capitalization of $0.45 billion, making it a small-cap company.

Does MNPR pay dividends?

No, Monopar Therapeutics Inc. does not currently pay a dividend to shareholders.